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Transforming healthcare through
regenerative medicine
Zita M. Jessop1,2,3, Ayesha Al-Sabah1,3, Wendy R. Francis3 and Iain S. Whitaker1,2,3*
Abstract
Regenerative medicine therapies, underpinned by the core principles of rejuvenation, regeneration and
replacement, are shifting the paradigm in healthcare from symptomatic treatment in the 20th century to curative
treatment in the 21st century. By addressing the reasons behind the rapid expansion of regenerative medicine
research and presenting an overview of current clinical trials, we explore the potential of regenerative medicine to
reshape modern healthcare.
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Background
The current dilemmas for modern day healthcare, such
as an aging population and the increasing prevalence of
chronic diseases, require solutions that limit organ dys-
function and tissue degeneration and which potentially
offer replacement. This was first addressed through
transplantation, a field that advanced rapidly in the
1950s through a combination of surgical innovations
and fundamental scientific breakthroughs in immuno-
suppression [1]. In contrast to the allogenic replacement
of transplantation, regenerative medicine seeks to apply
stem cell research with developmental biology principles
to regenerate cells, tissues and organs de novo [2].
The regenerative medicine research field resulted from
the convergence of multiple scientific avenues, such as suc-
cessful culture of cells in the laboratory [3], identification,
characterization and differentiation of stem cells [4–7], and
an improved understanding of developmental and molecu-
lar biology [8], to conceivably allow control of the intracel-
lular and extracellular environment to promote tissue and
organ formation in the laboratory (Fig. 1).
Regenerative medicine has been recognized worldwide
as a developing research field that offers the potential to
revolutionize patient care in the 21st century [9]. The
prospect of addressing massive healthcare markets, such
as cardiovascular disease, neurological conditions or
chronic metabolic diseases (e.g. end-stage renal disease
or diabetes), means that there has been sustained scien-
tific, public and commercial interest despite early set-
backs and slow progress.
Expansion and potential impact of regenerative
medicine
Demand for regenerative medicine products has been
driven by an increase in degenerative and chronic diseases
which place cost pressures on healthcare providers, com-
bined with advances in new technologies such as nano-
technology, bioengineering and stem cell therapy [10].
Long-term cell, tissue and organ replacement will not only
provide an alternative to transplantation [11], but will also
provide therapeutic options for degenerative conditions
(e.g. neurodegenerative conditions (Parkinson’s), stroke
and heart failure), which are currently only managed
through palliation [12, 13].
According to the World Regenerative Medicines
Market forecast for 2013–2020 [14], the global re-
generative medicines market for small molecules and
biologics, gene therapy and cell therapy is expected
to reach $67.5 billion by 2020, which is an increase
of $51.1 billion from 2013, thus reflecting its com-
mercial potential. Governments across Europe and
the US, as well as their medical research councils,
have identified tissue engineering and regenerative
medicine at the top of their research priorities [9].
Removal of previous restrictions in embryonic stem
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Fig. 1 Regenerative medicine origins
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cell research in 2009 by the Obama organization is
predicted to contribute to further considerable
growth within the field as well as improved potential
for clinical translation [15].
Clinical trials in regenerative medicine
The expansion of regenerative medicine as a scientific
discipline, with its core principles of rejuvenation, regen-
eration and replacement (the 3R’s), is shifting the
Table 1 Applications of regenerative medicine therapies in different medical specialties
Medical
Speciality
Pathology Cell/Tissue Therapy Clinical Trial Phase Patient numbers Clinical Trial
StudyPubmed Clinical
Trial database
Neurology Parkinson’s Fetal porcine cells
Transplantation of embryonic dopamine
neurons
I, II 34 Fink 2001;
Freed 2001
Paraplegia, Spinal cord
injuries
MSCs transplanted directly into injured
spinal cord.
Bone marrow nucleated cells injected
intrathecally and intravenously coupled
with MSC infusion by lumbar puncture
I, II 80 Park 2012;
Jarocha 2015
Multiple Sclerosis IV infusion of MSCs
Haemopoietic stem cell transplants
I, II 30 Connick 2012
Cardiology Ischaemic cardiomyopathy,
heart failure
Transendocardial injection of MSC
derived from BM or adipose tissue
Intracoronary injection of cardiac
stem cells IV infusion of MSC
I, II 104 Heldman 2014;
Hare 2014; Chugh
2012; Perin 2014
Respiratory Idiopathic pulmonary
fibrosis
IV infusion of placental- Chambers
derived MSC
I 8 Chambers 2014
Chronic lung disease IV infusion of HLA-matched allogeneic
MSCs derived from BM/umbilical cord
I,II 62 Weiss 2013
Rheumatology Osteoarthritis Intra-articular injection of autologous
or allogeneic MSC
I, II, III 104 Orozco 2013;
Jo 2014
Osteogenesis Imperfecta Allogeneic bone marrow derived MSC
Haemopoietic stem cell transplant plus
MSC infusion
I 8 Horwitz 2002;
Horwitz 2002
Orthopaedics Fracture healing;
Joint resurfacing;
Osteoporosis
MSC combined with/without calcium
sulphate
Allogenic bone graft containing stem cells
G-CSF-mobilised Haemopoietic stem
cells with collagen scaffold for
non-union fracture healing
I,II 96 Kuoroda 2014;
Jones 2015;
Bajada 2007
Haematology Hematopoietic stem cell
transplant (HSCT); Graft
versus Host Disease (GvHD)
Prochymal (MSC) for severe refractory
acute GvHD
MSC infused with or following
hematopoietic stem cell transplant
I, II, III 240 Prasad 2011;
Ringden 2006;
Perez-Simon 2011
Opthalmology Macular degeneration ESC-derived retinal pigment epithelium I 2 Schwartz 2012
Gastroenterology Liver cirrhosis;
Decompensated liver
disease
MSC injected into peripheral or portal
vein
Autologous bone marrow mononuclear
cells infused IV for liver cirrhosis
UC-MSC IV in fusion in decompensated
liver disease
I,II 45 Kharaziha 2009;
terai 2006;
Zhang 2012
Crohn’s disease Autologous hematopoietic)stem cell
transplantation for refractory Crohn’s
I, II, III 98 Oyama 2005
Endocrinology Diabetes (type I & 2) Stem cell educator therapy with cord
blood derived stem cells for insulin
resistant type II diabetes
Hematopoietic stem cell transplantation
for new onset type I diabetes
I, II 65 Zhao 2013,
D’Addio 2014
Nephrology/
Urology
Kidney transplant
rejection
MSC based therapy to prevent rejection
in living-related kidney transplants
I, II 159 Tan 2012
MSC mesenchymal stem cells, BM Bone marrow, ESC Embryonic Stem cells, iPSC induced Pluripotent stem cells, IV intravenous, G-CSF granulocyte-colony stimulating
factor, 3D 3-dimensional, UC umbilical cord
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paradigm in healthcare from symptomatic treatment in
the 20th century to curative treatment in the 21st
century [13]. This is evidenced by the rapid increase in
regenerative medicine clinical trials in each specialty
[16, 17], which can be broadly classified as using either
cell- or tissue-based products (Table 1). The Food and
Drug Administration in the US and the European Medi-
cines Agency have more complex classification systems of
regenerative medicine products, including cellular therapy,
gene therapy, stimulators of endogenous repair, biologic-
device combination products, and human tissue and
xenotransplantation [18]. Broadly, the regulatory require-
ments can be based on the pillars of sterility, stability and
potency, and these need to be addressed prior to success-
ful clinical translation in the future (Table 2).
Cell-based therapies work either via stimulation of en-
dogenous repair through extracellular factors or differ-
entiation and functional replacement of endogenous cell
types [17]; they include stem cell implantation or infu-
sion to treat hematopoietic diseases, cardiac conditions
and Parkinson’s disease. Most of the pioneering work
has been performed using haematopoietic stem cells due
to the early bone marrow transplant work, making them
the most well-studied stem cell type [19]. In particular,
adult mesenchymal stem cells have gained interest as
they avoid the ethical concerns of using embryonic stem
cells, can be rapidly expanded in vitro and avoid im-
munogenicity. Studies have shown contradictory results
on the efficacy of the transplanted cells, with patient
variability with regards to response (Table 1); further
work is needed to elucidate cell identity and health to
ensure patient safety (Table 2).
The tissue engineering strand of regenerative medicine
incorporates cells with biodegradable scaffolds to engin-
eer replacement tissues like dermis or cartilage [20] and
whole organs such as trachea and bladder [21, 22]. Limi-
tations of synthetic polymer scaffolds, such as infection,
extrusion and degradation product toxicity, have encour-
aged interest in decellularised matrices as well biologics
for use as scaffolds as one of the more effective ways of
replicating native tissue anisotropy [21, 22]. Decellularised
matrices provide durability, enhanced integration and bio-
compatibility whilst avoiding allosensitization [21]. This
may explain why many of the significant breakthroughs
and first-in-man studies have utilized this technique com-
bined with autologous cell-seeding with some success
[21–23], and even showed promise in vitro for more com-
plex structures such as pulmonary and aortic valves as
well as whole organs such as heart and liver [24, 25]. How-
ever, despite early interest and investment in tissue engin-
eering research, with annual R&D spending estimated at
US$580 million, initial clinically applicable product release
has been slow but steady [26].
Controversies in the field
The regenerative medicine field has been shrouded in
controversy. Significant potential gains have led to
several high profile allegations of research misconduct
[27, 28]. There is also a growing stem cell tourism indus-
try based on unproven treatments that aims to capitalize
on stem cell hype [29, 30]. Desperate patients would ra-
ther approach private clinics offering experimental stem
cell treatments, with unproven safety and efficacy pro-
files, than wait for outcomes of clinical trials [30]. Media
coverage and direct advertising of stem cell therapies as
well as the political, ethical and religious controversies
surrounding human embryonic stem cells, can contrib-
ute not only to increased public awareness but also in-
flated expectations of regenerative medicine products,
and there continues to be a significant gap between the
perceived and realistic benefits [31]. A concerted effort
from the scientific community as well as robust outcome
data from clinical trials will be needed to temper unreal-
istic claims [16, 17].
Conclusion
Medical breakthroughs often require the convergence of
multiple scientific advances for which interdisciplinary
collaboration is fundamental. Similar to transplant medi-
cine, regenerative medicine requires the convergence of a
number of scientific disciplines, including stem cell biol-
ogy, developmental and molecular biology, engineering
Table 2 Overview of testing of regenerative medicine products to validate sterility, stability and potency
Pillar Obstacles Method Reference
Sterility Sterility testing Direct inoculation test in aerobic and anaerobic media [32]
Stability Chromosomal stability Karyotyping [33]
Cell metabolism Mitochondrial bioenergetics [34]
Safety Animal testing to investigate interactions between native
tissue and product
[35]
Potency Cell identity Flow cytometry and immunohistochemical analysis [36]
Reproducibility Purity and viability of cell population [37]
Cell tracking Fluorescent/superparamagnetic iron oxide cell labeling
prior to animal implantation
[35]
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and biomaterials. Despite media hype, scientific overclaim
and unrealistic expectations, which have been previously
witnessed for a number of healthcare technologies, regen-
erative medicine continues to make steady progress
reflected by the increasing number of clinical trials
[16, 17]. Significant potential has been demonstrated in
the cell therapy field to treat haematological, neurological
and rheumatological conditions. The tissue engineering
field, although holding great promise, still has some way
to develop before the excitement surrounding novel bio-
fabrication strategies, such as 3D bioprinting, is translated
to patient care. The fast moving and versatile field of re-
generative medicine is at the cutting edge of translational
research and could shift the paradigm in healthcare from
symptomatic to curative treatment. BMC Medicine is very
interested in breakthroughs in regenerative medicine/stem
cell therapy and submission of such relevant articles is
encouraged.
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